Livdelzi: Dosage Form, Projected Sales, NCE-1 Date | Seladelpar

Livdelzi

Livdelzi is used to treat primary biliary cholangitis (PBC). The purpose of Livdelzi is to efficiently target PPARδ, a peroxisome proliferator-activated receptor delta that inhibits the formation of bile acids.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Seladelpar
Innovator :

GILEAD SCIENCES INC
Approval Date :

14-Aug-24
NCE-1 Date :

14-Aug-28
NCE Date :

14-Aug-29
Dosage Form :

Capsule
Strength :

10mg
Therapeutic Category :

Hepatoprotective Agents
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

241
2026 :

597
2027 :

942
2028 :

1,317
2029 :

1,638
2030 :

1,888
2031 :

1,784

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Livdelzi

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?